Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity

K. Groot, J. Horváth, R. Z. Cai, A. V. Schally

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bombesin-like and GRP-like peptides may act as autocrine growth factors in the proliferation of some cancers. A pseudononapeptide bombesin antagonist, [D-Tpi6,Leu13Ψ (CH2NH)-Leu14]bombesin(6-14), and related analogs synthesized in our laboratory significantly inhibit tumor growth in various cancer models. A radioimmunoassay (RIA), suitable for determination of RC-3095 and its congeners in unextracted serum, was developed in order to facilitate further experimental and clinical evaluation of this bombesin/GRP receptor antagonist for the treatment of various tumors. Antibodies were generated against RC-3095 and Des-Tpi1-RC-3095, conjugated to bovine serum albumin with glutaraldehyde. Antiserum JH-631b was selected for further experiments based on the antibody characterization. At an antiserum dilution of 1:189000, this antibody bound approximately 50% of 7 fmol of added radiolabeled Tyr1-RC-3095. The antibody cross-reacted with C-terminal fragments of RC-3095. Fragments without the C-terminus and naturally existing peptides of the bombesin family or structurally unrelated peptides did not cross-react. The minimum detectable dose of RC-3095 was 0.4 pg/tube. Intra- and interassay coefficients of variation ranged from 3.2 to 4.4% and from 5.6 to 12.8%, respectively. The RIA is suitable for direct determination of RC-3095 in serum. The RIA should be of value for monitoring levels of this analog in serum during long-term therapy.

Original languageEnglish
Pages (from-to)561-566
Number of pages6
JournalInternational Journal of Peptide and Protein Research
Volume45
Issue number6
Publication statusPublished - 1995

Fingerprint

Bombesin
Radioimmunoassay
Antibodies
Peptides
Tumors
Immune Sera
Neoplasms
Serum
Bombesin Receptors
Glutaral
Bovine Serum Albumin
Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-bombesin (6-14)
Dilution
Intercellular Signaling Peptides and Proteins
Monitoring
Growth

Keywords

  • Bombesin antagonists
  • Cancer
  • Immunization
  • Radioimmunoassay

ASJC Scopus subject areas

  • Biochemistry

Cite this

Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. / Groot, K.; Horváth, J.; Cai, R. Z.; Schally, A. V.

In: International Journal of Peptide and Protein Research, Vol. 45, No. 6, 1995, p. 561-566.

Research output: Contribution to journalArticle

@article{c638c6e44c2a43d4ae7a2bc684976978,
title = "Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity",
abstract = "Bombesin-like and GRP-like peptides may act as autocrine growth factors in the proliferation of some cancers. A pseudononapeptide bombesin antagonist, [D-Tpi6,Leu13Ψ (CH2NH)-Leu14]bombesin(6-14), and related analogs synthesized in our laboratory significantly inhibit tumor growth in various cancer models. A radioimmunoassay (RIA), suitable for determination of RC-3095 and its congeners in unextracted serum, was developed in order to facilitate further experimental and clinical evaluation of this bombesin/GRP receptor antagonist for the treatment of various tumors. Antibodies were generated against RC-3095 and Des-Tpi1-RC-3095, conjugated to bovine serum albumin with glutaraldehyde. Antiserum JH-631b was selected for further experiments based on the antibody characterization. At an antiserum dilution of 1:189000, this antibody bound approximately 50{\%} of 7 fmol of added radiolabeled Tyr1-RC-3095. The antibody cross-reacted with C-terminal fragments of RC-3095. Fragments without the C-terminus and naturally existing peptides of the bombesin family or structurally unrelated peptides did not cross-react. The minimum detectable dose of RC-3095 was 0.4 pg/tube. Intra- and interassay coefficients of variation ranged from 3.2 to 4.4{\%} and from 5.6 to 12.8{\%}, respectively. The RIA is suitable for direct determination of RC-3095 in serum. The RIA should be of value for monitoring levels of this analog in serum during long-term therapy.",
keywords = "Bombesin antagonists, Cancer, Immunization, Radioimmunoassay",
author = "K. Groot and J. Horv{\'a}th and Cai, {R. Z.} and Schally, {A. V.}",
year = "1995",
language = "English",
volume = "45",
pages = "561--566",
journal = "International Journal of Peptide and Protein Research",
issn = "0367-8377",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity

AU - Groot, K.

AU - Horváth, J.

AU - Cai, R. Z.

AU - Schally, A. V.

PY - 1995

Y1 - 1995

N2 - Bombesin-like and GRP-like peptides may act as autocrine growth factors in the proliferation of some cancers. A pseudononapeptide bombesin antagonist, [D-Tpi6,Leu13Ψ (CH2NH)-Leu14]bombesin(6-14), and related analogs synthesized in our laboratory significantly inhibit tumor growth in various cancer models. A radioimmunoassay (RIA), suitable for determination of RC-3095 and its congeners in unextracted serum, was developed in order to facilitate further experimental and clinical evaluation of this bombesin/GRP receptor antagonist for the treatment of various tumors. Antibodies were generated against RC-3095 and Des-Tpi1-RC-3095, conjugated to bovine serum albumin with glutaraldehyde. Antiserum JH-631b was selected for further experiments based on the antibody characterization. At an antiserum dilution of 1:189000, this antibody bound approximately 50% of 7 fmol of added radiolabeled Tyr1-RC-3095. The antibody cross-reacted with C-terminal fragments of RC-3095. Fragments without the C-terminus and naturally existing peptides of the bombesin family or structurally unrelated peptides did not cross-react. The minimum detectable dose of RC-3095 was 0.4 pg/tube. Intra- and interassay coefficients of variation ranged from 3.2 to 4.4% and from 5.6 to 12.8%, respectively. The RIA is suitable for direct determination of RC-3095 in serum. The RIA should be of value for monitoring levels of this analog in serum during long-term therapy.

AB - Bombesin-like and GRP-like peptides may act as autocrine growth factors in the proliferation of some cancers. A pseudononapeptide bombesin antagonist, [D-Tpi6,Leu13Ψ (CH2NH)-Leu14]bombesin(6-14), and related analogs synthesized in our laboratory significantly inhibit tumor growth in various cancer models. A radioimmunoassay (RIA), suitable for determination of RC-3095 and its congeners in unextracted serum, was developed in order to facilitate further experimental and clinical evaluation of this bombesin/GRP receptor antagonist for the treatment of various tumors. Antibodies were generated against RC-3095 and Des-Tpi1-RC-3095, conjugated to bovine serum albumin with glutaraldehyde. Antiserum JH-631b was selected for further experiments based on the antibody characterization. At an antiserum dilution of 1:189000, this antibody bound approximately 50% of 7 fmol of added radiolabeled Tyr1-RC-3095. The antibody cross-reacted with C-terminal fragments of RC-3095. Fragments without the C-terminus and naturally existing peptides of the bombesin family or structurally unrelated peptides did not cross-react. The minimum detectable dose of RC-3095 was 0.4 pg/tube. Intra- and interassay coefficients of variation ranged from 3.2 to 4.4% and from 5.6 to 12.8%, respectively. The RIA is suitable for direct determination of RC-3095 in serum. The RIA should be of value for monitoring levels of this analog in serum during long-term therapy.

KW - Bombesin antagonists

KW - Cancer

KW - Immunization

KW - Radioimmunoassay

UR - http://www.scopus.com/inward/record.url?scp=0029032868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029032868&partnerID=8YFLogxK

M3 - Article

C2 - 7558587

AN - SCOPUS:0029032868

VL - 45

SP - 561

EP - 566

JO - International Journal of Peptide and Protein Research

JF - International Journal of Peptide and Protein Research

SN - 0367-8377

IS - 6

ER -